STOCK TITAN
  1. Home
  2. News
  3. ALNY

Alnylam Pharmaceuticals Inc - ALNY STOCK NEWS

Welcome to our dedicated news page for Alnylam Pharmaceuticals (Ticker: ALNY), a resource for investors and traders seeking the latest updates and insights on Alnylam Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Alnylam Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Alnylam Pharmaceuticals's position in the market.

News
Alnylam to Webcast Presentation at Canaccord Genuity 43rd Annual Growth Conference
Rhea-AI Summary
ALNY - Alnylam Pharmaceuticals to Present Company Overview at Canaccord Genuity 43rd Annual Growth Conference on August 10, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.08%
Tags
conferences
-
News
Alnylam Announces Partnership with Roche to Co-Develop and Co-Commercialize Zilebesiran, an Investigational RNAi Therapeutic for the Treatment of Hypertension in Patients with High Cardiovascular Risk
Rhea-AI Summary
Alnylam Pharmaceuticals has entered into a strategic agreement with Roche to develop and commercialize zilebesiran, an investigational RNAi therapeutic for the treatment of hypertension. Alnylam will receive an upfront cash payment of $310 million and is eligible for additional milestone payments, bringing the potential deal value up to $2.8 billion. Alnylam and Roche will co-commercialize zilebesiran in the U.S., while Roche obtains exclusive rights to commercialize it outside the U.S. Zilebesiran has shown promising results in Phase 1 studies, demonstrating consistent and durable blood pressure reduction. The partnership aims to disrupt the hypertension treatment paradigm globally and advance Alnylam's P5x25 strategy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.87%
Tags
partnership
-
News
Alnylam to Webcast Conference Call Discussing Second Quarter 2023 Financial Results
Rhea-AI Summary
Alnylam Pharmaceuticals, Inc. will report financial results for Q2 2023 on August 3, 2023. The management will provide an update on the company and discuss Q2 results and future expectations via a conference call. Participants are requested to register in advance. A replay of the call will be available on the website for six months.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.89%
Tags
conferences earnings
News
Alnylam Announces Publication of Phase 1 Study Results for Zilebesiran in the New England Journal of Medicine
Rhea-AI Summary
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) - Phase 1 study results of zilebesiran, an RNAi therapeutic for hypertension, published in NEJM, show dose-dependent reductions in serum angiotensinogen and 24-hour ambulatory blood pressure sustained for six months after single doses of ≥200 mg. Acceptable safety profile supporting further development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.89%
Tags
clinical trial
-
News
Alnylam Reports Updated Positive Interim Phase 1 Results for ALN-APP, in Development for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
Rhea-AI Summary
Alnylam Pharmaceuticals announced positive interim results for the Phase 1 study of ALN-APP, an RNAi therapeutic for Alzheimer's disease. The study showed rapid and sustained target engagement over 6 months with a single dose. ALN-APP also demonstrated a good safety profile. The multiple-dose portion of the study is being initiated in approved regions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.91%
Tags
clinical trial
-
News
Alnylam Announces Date of Planned FDA Advisory Committee Meeting for ONPATTRO® (patisiran) for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.59%
Tags
none
News
Alnylam to Webcast Presentation at Goldman Sachs 44th Annual Global Healthcare Conference
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.34%
Tags
conferences
-
News
Alnylam Presents 18-Month Results from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
News
Alnylam Pharmaceuticals Reports First Quarter 2023 Financial Results and Highlights Recent Period Activity
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.95%
Tags
earnings
News
Alnylam to Webcast Presentation at BofA Securities 2023 Health Care Conference
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.95%
Tags
conferences
Stock ALNY logo
Alnylam Pharmaceuticals Inc

Nasdaq:ALNY

ALNY Rankings

#547 Ranked by Market Cap
#3694 Ranked by Stock Gains
N/A Ranked by Dividends

ALNY Stock Data

18.55B
125.41M
0.41%
95.02%
2.21%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Cambridge

About ALNY

alnylam is developing an entirely new class of innovative medicines based on a breakthrough discovery in biology known as rna interference, or rnai. with rnai technology, we have the opportunity to treat disease and impact the lives of patients in a fundamentally new way by silencing disease-causing genes upstream of today's medicines.